Zhang L, Zhang Q, Tang Y, et al. LOVD‐DASH: A Comprehensive LOVD database coupled with diagnosis and an at--risk assessment system for hemoglobinopathies. Human Mutation. 2019;40:2221--2229. 10.1002/humu.23863 31286593

1. INTRODUCTION {#humu23863-sec-0010}
===============

Hemoglobinopathies are the most common monogenic disorders worldwide. The major β‐hemoglobinopathies, especially sickle cell disease and β‐thalassemia are lethal hemoglobinopathies that have caused global health burdens due to their serious pathogenicity and high prevalence (Taher, Weatherall, & Cappellini, [2018](#humu23863-bib-0023){ref-type="ref"}; Weatherall., [2010](#humu23863-bib-0029){ref-type="ref"}). Previous efforts and programs for preventing hemoglobinopathies have proved to be effective in the Mediterranean populations, especially for β‐thalassemia, showing a reduction from 1:250 live births to 1:1660 in 2009 (Cao & Kan, [2013](#humu23863-bib-0005){ref-type="ref"}). The birth rates of hemoglobinopathies, however, remain high. In China, approximately 12,900 newborns are estimated with hemoglobin disorders of various types each year, which in turn may cause a serious social burden (Shang et al., [2017](#humu23863-bib-0022){ref-type="ref"}; Xiong et al., [2010](#humu23863-bib-0030){ref-type="ref"}). The number of fetuses with hemoglobinopathies can be largely reduced if a robust system for clinicians is developed to master standard guidelines and to rapidly make correct clinical management choices for hemoglobinopathy patients or at‐risk couples.

Previous observations involving hemoglobin switching have shown that elevated fetal hemoglobin expression ameliorates the severity of β‐hemoglobinopathies (Vinjamur, Bauer, & Orkin, [2017](#humu23863-bib-0027){ref-type="ref"}). Thus, an accurate diagnosis of hemoglobinopathies calls for not only the proper genotyping of the disease‐causing mutations in globin gene clusters, but also newly identified variants in modifier genes, such as *KLF1*, *BCL11A*, and *GATA1*, which are responsible for altered expression of γ‐globin and also influence β‐thalassemia severity (Bauer & Orkin, [2015](#humu23863-bib-0003){ref-type="ref"}; D. Liu et al., [2014](#humu23863-bib-0014){ref-type="ref"}; Thein et al., [2007](#humu23863-bib-0025){ref-type="ref"}). Substantial effort has been made to establish the databases to record global mutation spectra causing and modifying hemoglobinopathies (Giardine et al., [2011](#humu23863-bib-0008){ref-type="ref"}; Kountouris et al., [2014](#humu23863-bib-0013){ref-type="ref"}). HbVar, built by Giardine et al. (Hardison et al., [2002](#humu23863-bib-0011){ref-type="ref"}) has thus far been an authoritative hemoglobinopathy database for both researchers and clinicians. We present herein a comprehensive variant database of hemoglobinopathies focusing on a Chinese population, recording the details of all reported variants through literature peer review‐curation and existing databases. Moreover, unpublished data from our laboratory, including all the phenotype--genotype datasets derived from high‐throughput sequencing data of 2,087 hemoglobinopathy patients and 20,222 general southern Chinese individuals, were also merged into the database (Shang et al., [2017](#humu23863-bib-0022){ref-type="ref"}). The addition of 34 novel functional variants from these genes has been detected using this high‐throughput approach. All the variants are classified according to American College of Medical Genetics and Genomics (ACMG) recommendations with the use of specific standard terminology: "pathogenic", "likely pathogenic", "uncertain significance", "likely benign", and "benign". (Richards et al., [2015](#humu23863-bib-0021){ref-type="ref"}; Table S1). Details of all the variants are integrated into the Leiden Open Variation Database, which is available at <http://www.genomed.zju.edu.cn/LOVD3/genes>.

An online auxiliary diagnosis and at‐risk assessment system for inherited hemoglobinopathy (DASH) has also been established based on the following: (a) the integrity of the hemoglobinopathy mutation spectrum of a Chinese population; (b) the availability of a comprehensive phenotype‐genotype data set corresponding to the 22,309 samples; and (c) the detailed information of variants according to the latest version of HbVar (Giardine et al., [2014](#humu23863-bib-0009){ref-type="ref"}). Aiming to accomplish the molecular screening and clinical genotyping of hemoglobinopathies in a Chinese population, DASH consists of three main workflows. DASH not only infers the thalassemia trait based on the input of the hematologic phenotype but also recognizes the uploaded copy number variants (CNVs) and single nucleotide variants (SNVs) data then interprets the data with a specific hemoglobinopathy annotation library. Both disease‐causing and modifier variants will be evaluated for a combined analysis, which will ultimately lead to an overall hemoglobinopathy diagnosis. Furthermore, the system will conduct an at‐risk assessment of known disease‐causing mutations and reveal critical clinical information for potential offspring. A diagnostic and assessment report will be automatically presented which could provide accurate suggestions on diagnosis and genetic counseling of hemoglobinopathies. DASH is available at <http://www.smuhemoglobinopathy.com>.

In this study, we portrayed the most comprehensive mutation spectrum of hemoglobinopathies in the Chinese population. In addition, LOVD‐DASH will make a contribution in research and clinical application and provide a new method for treatment and precaution of hemoglobinopathies in Chinese patients. With the LOVD database and DASH system, we are one step closer to complete molecular screening and accurate clinical genotyping of hemoglobinopathies.

2. METHODS AND RESULTS {#humu23863-sec-0020}
======================

2.1. LOVD database of hemoglobinopathy variants in a Chinese population {#humu23863-sec-0030}
-----------------------------------------------------------------------

### 2.1.1. Data collection and database content {#humu23863-sec-0040}

The bulk of data on gene variants was derived from published data, including databases (HbVar: <http://globin.cse.psu.edu/>; IthaGenes: <http://www.ithanet.eu/db/ithagenes>), literature mining from PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), and Chinese core journals (<http://xueshu.baidu.com/>). The other source is unpublished data from our laboratory, including phenotype‐genotype datasets derived from high‐throughput sequencing data of 2,087 patients with hemoglobinopathy and 20,222 general previously mentioned southern Chinese individuals. The study was approved by the Medical Ethics Committee in accordance with the Declaration of Helsinki. All the clinical data of participants have been obtained and curated under agency ethical guidelines. Variations in globin genes (*HBA1,* MIM\# 141800; *HBA2,* MIM\# 141850; *HBB,* MIM\# 141900; *HBG1,* MIM\# 142200; *HBG2,* MIM\# 142250; *HBD,* MIM\# 142000) and nonglobin genes (*BCL11A,* MIM\# 606557; *KLF1,* MIM\# 600599; *GATA1,* MIM\# 305371), as well as the intergenic region of *HMIP* (MIM\# 142470), were categorized into disease‐causing and modifiers, and would be accepted as keywords to perform literature mining on hemoglobinopathies. Currently, 371 unique variants have been recorded; 265 of the 371 unique variants were described as disease‐causing variants, while 106 were defined as modifier variants (Table [1](#humu23863-tbl-0001){ref-type="table"}), including 34 functional variants identified by a quantitative trait association study of the high‐throughput sequencing data in Plink (Figure S1; Table [2](#humu23863-tbl-0002){ref-type="table"}; Table S2). The inevitable bias caused by haplotype that the causative variant(s) among them cannot be judged simply by statistical approaches. For further research, the corresponding phenotypic information and genotypic data, including disease‐causing and identified modifier variants in detail of 2,087 hemoglobinopathy cohort were displayed in <http://www.genomed.zju.edu.cn/LOVD3/individuals>.

###### 

Summary of disease‐causing and modifier variants of hemoglobinopathies in LOVD‐China

  Disease‐causing variants                                                                                
  ----------------------------------------------------- --------- --------- --------- --------- --------- ---------
  OMIM                                                  141900    141800    141850    142000    142200    142250
  Location                                              11p15.4   16p13.3   16p13.3   11p15.4   11p15.4   11p15.4
  Pathogenicity                                                                                           
  Hb variant                                            28        6         13        4         2         2
  Thalassemia                                           92        27        33        17        0         0
  HPFH[^b^](#humu23863-tbl1-note-0004){ref-type="fn"}   2         0         0         2         1         0
  Uncertain significance                                2         11        8         2         8         5
  Total                                                 124       44        54        25        11        7

  Modifier variants                                                               
  ------------------------ ---------- -------- -------------- --------- --------- ---------
  OMIM                     600599     606557   142470         305371    142200    142250
  Location                 19p13.13   2p16.1   6q22.3--23.1   Xp11.23   11p15.4   11p15.4
  Modification                                                                    
  Elevated Hb F Level      18         3        17             0         5         4
  Decreased Hb F Level     0          9        3              0         4         7
  Uncertain significance   1          1        24             7         0         3
  Total                    19         13       44             7         9         14

*Note*: All the variants are classified according to ACMG recommendations. The pathogenicity was described as Hb variant, thalassemia, and hereditary persistence fetal hemoglobin (HPFH). "Hb variant" includes not only variants result in clinical significance, but all the reported abnormal hemoglobin variants. Modifier variants refer to all the collectible variants reported to be HbF‐related or be significant in influencing the severity of hemoglobinopathies in the Chinese population. Variants in disease‐causing genes without known pathogenicity were defined as the variants with "uncertain significance" (VUS). "Uncertain significance" in modifier variants, especially in *HMIP* region, refers to the variants reported to be HbF‐related but with unclear modification.

Abbreviations: ACMG, American College of Medical Genetics and Genomics; LOVD, LOVD, Leiden Open Variation Database; OMIM, Online Mendelian Inheritance in Man

Appropriately, *HBG1* and *HBG2* genes can be classed as modifier genes. "Hb variant" in these genes referred to the variants which lead to abnormal fetal hemoglobin such as Hb F‐Jiangsu (*HBG1*:c.403G\>A).

HPFH involves only the deletion forms.

Although bulks of modifier variants have been detected in non‐globin genes like *BCL11A* or *HMIP* region etc., functional variants within *KLF1* have the most clinical significant influence on the severity of β‐hemoglobinopathies in Chinese population.

Variants in erythroid transcription factors *GATA1* are reported to be related with HbF, HbA2, and severity of hemoglobinopathies.
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###### 

Functional variants from 22,309 high‐throughput sequencing data

  SNPs          Locus      Location[^a^](#humu23863-tbl2-note-0003){ref-type="fn"}   Nucleotide change   Frequency   Modification    *P*‐value         HbF level of carriers(g/L)   HbF level of non‐carriers(g/L)
  ------------- ---------- --------------------------------------------------------- ------------------- ----------- --------------- ----------------- ---------------------------- --------------------------------
  rs61749494    *BCL11A*   2:60689441                                                T\>C                0.251       Elevated HbF    4.24 × 10^−6^     18.6820                      11.6439
  rs10189857    *BCL11A*   2:60713235                                                A\>G                0.9235      Decreased HbF   1.64 × 10^−6^     12.8591                      20.0668
  rs6545816     *BCL11A*   2:60714861                                                A\>C                0.9216      Decreased HbF   3.24 × 10^−6^     12.8711                      19.7456
  rs1427407     *BCL11A*   2:60718043                                                T\>G                0.9275      Decreased HbF   1.95 × 10^−6^     12.9450                      19.3588
  rs7599488     *BCL11A*   2:60718347                                                C\>T                0.9235      Decreased HbF   2.77 × 10^−6^     12.8542                      20.1268
  rs766432      *BCL11A*   2:60719970                                                C\>A                0.9255      Decreased HbF   1.65 × 10^−5^     13.0060                      18.4325
  rs4671393     *BCL11A*   2:60720951                                                A\>G                0.9275      Decreased HbF   3.43 × 10^−6^     12.9880                      18.8090
  rs375867652   *HMIP*     6:135419038                                               delC                0.3275      Elevated HbF    1.59 × 10^−4^     17.3037                      11.5147
  rs11759553    *HMIP*     6:135422296                                               A\>T                0.3451      Elevated HbF    5.61 × 10^−5^     17.2904                      11.3657
  rs35959442    *HMIP*     6:135424179                                               C\>G                0.349       Elevated HbF    6.06 × 10^−5^     17.2321                      11.3613
  rs4895440     *HMIP*     6:135426558                                               A\>T                0.349       Elevated HbF    6.06 × 10^−5^     17.2321                      11.3613
  rs4895441     *HMIP*     6:135426573                                               A\>G                0.349       Elevated HbF    6.06 × 10^−5^     17.2321                      11.3613
  rs9402686     *HMIP*     6:135427817                                               G\>A                0.351       Elevated HbF    6.06 × 10^−5^     17.1452                      11.3906
  rs9494142     *HMIP*     6:135431640                                               T\>C                0.3627      Elevated HbF    5.17 × 10^−5^     16.9296                      11.4070
  rs6934903     *HMIP*     6:135451564                                               T\>A                0.3373      Elevated HbF    9.34 × 10^−5^     16.6348                      11.7694
  rs78981054    *HBG1*     11:5270347                                                delAAAG             0.9863      Decreased HbF   4.66 × 10^−8^     13.1293                      33.6006
  rs34879481    *HBG2*     11:5274452                                                insT                0.1392      Elevated HbF    4.19 × 10^−12^    23.3682                      11.7998
  rs28379094    *HBG1*     11:5269806                                                C\>T                0.9843      Decreased HbF   1.65 × 10^--12^   13.0232                      37.7005
  rs2187608     *HBG1*     11:5269931                                                G\>C                0.1373      Elevated HbF    1.41 × 10^--12^   23.3314                      11.832
  rs7482933     *HBG1*     11:5270002                                                G\>A                0.8588      Decreased HbF   1.15 × 10^--9^    11.8743                      22.7546
  rs2855039     *HBG1*     11:5271671                                                C\>T                0.1373      Elevated HbF    6.93 × 10^--12^   23.3314                      11.832
  rs2855038     *HBG1*     11:5272154                                                T\>C                0.9863      Decreased HbF   4.46 × 10^--11^   13.1293                      33.6006
  rs2855036     *HBG1*     11:5272682                                                C\>T                0.1373      Elevated HbF    1.30 × 10^--11^   23.3314                      11.832
  rs2070972     *HBG2*     11:5274717                                                A\>C                0.9843      Decreased HbF   5.86 × 10^--11^   13.1411                      30.303
  rs11036474    *HBG2*     11:5275178                                                T\>C                0.1412      Elevated HbF    7.90 × 10^--12^   23.3499                      11.7764
  rs11036475    *HBG2*     11:5275240                                                G\>A                0.9863      Decreased HbF   2.06 × 10^--11^   13.1293                      33.6006
  rs11036476    *HBG2*     11:5275343                                                C\>T                0.9863      Decreased HbF   9.69 × 10^--11^   13.1293                      33.6006
  rs2070973     *HBG2*     11:5275407                                                T\>C                0.9863      Decreased HbF   9.69 × 10^--11^   13.1293                      33.6006
  rs7482144     *HBG2*     11:5276169                                                G\>A                0.1412      Elevated HbF    1.81 × 10^--11^   23.3499                      11.7764
  rs2855123     *HBG2*     11:5277078                                                A\>T                0.9863      Decreased HbF   3.92 × 10^‐10^    13.1293                      33.6006
  rs2855122     *HBG2*     11:5277236                                                C\>T                0.9863      Decreased HbF   1.20 × 10^--11^   13.1293                      33.6006
  rs2855121     *HBG2*     11:5277291                                                C\>T                0.1392      Elevated HbF    7.90 × 10^--12^   23.3682                      11.7998
  rs34306743    *HBG1*     11:5272553                                                insA                0.1373      Elevated HbF    1.30 × 10^--11^   23.3314                      11.832
  rs483352838   *KLF1*     19:12996518                                               insGGCGCCG          0.0137      Elevated HbF    1.93 × 10^−6^     39.2343                      13.0509

*Note*: Among the 510 β^0^/β^0^ samples from 22,309 sequencing data, 74 variants were shown to be significant after association analysis in Plink judged by the *P*‐values after a Bonferroni correction. 34 of the variants were located in our candidate genes or the *HMIP* region. The 74 variants are available in the supplementary document.

Abbreviation: SNP, single nucleotide polymorphism.

The chromosomal locations are given in GRCh37/hg19 coordinates.

John Wiley & Sons, Ltd.

### 2.1.2. Database structure {#humu23863-sec-0050}

Taking *HBB* as an example (Figure [1](#humu23863-fig-0001){ref-type="fig"}), all the datasets are classified and presented in different columns including genes, transcripts, variants, individuals, diseases, and so forth. For instance, "individuals" column contains the basic information, genotypes, and phenotypes of all individuals with variants in the *HBB* gene. Besides, the homepage of the variant database consists of the following three sections: (a) The general information section contains basic information about the *HBB* gene. The reference sequences of *HBB* can be obtained in this section. The entries of public variants can be found in the "total number of public variants reported" listing. Detailed information of variants, such as DNA change, protein change, variant type, location, and the information of patients are available for download; (b) The graphical display section offers diagrams to show summary information of all variants in the database; (c) The linkage section shows other authoritative resources, the including HUGO Gene Nomenclature Committee (<https://www.genenames.org/>), Entrez gene (<http://www.ncbi.nlm.nih.gov/gene/>), Online Mendelian Inheritance in Man (OMIM; <http://www.omim.org>), the Human Gene Mutation Database (HGMD; <http://www.hgmd.cf.ac.uk/>), Genecards (<http://www.genecards.org/>), and the Genetic Testing Registry (GTR; <https://www.ncbi.nlm.nih.gov/gtr/>).

![Homepage of the *HBB* gene from our LOVD‐China database. LOVD, Leiden Open Variation Database](HUMU-40-2221-g001){#humu23863-fig-0001}

### 2.1.3. Data submission {#humu23863-sec-0060}

The LOVD‐China database is available for public submission. The submitter should register and sign in before submission. The literature or evidence which can support the clinical significance of the variants is required. Submitters should complete the variant data and corresponding phenotypic information in detail as much as possible. It is necessary that all variant data submitted should be named according to the nomenclature of the Human Genome Variation Society (HGVS; den Dunnen et al., [2016](#humu23863-bib-0007){ref-type="ref"}). The authors of this study are responsible for the manual curation of the database by checking each entry, adding new entries, and updating both existing variations and epidemiologic data. A more detailed introduction can be found in the documentation at <http://www.genomed.zju.edu.cn/LOVD3/docs/>.

2.2. Diagnosis and at‐risk assessment system of hemoglobinopathies {#humu23863-sec-0070}
------------------------------------------------------------------

### 2.2.1. DASH structure {#humu23863-sec-0080}

We integrated LOVD‐China, the 22,309 phenotype‐genotype individual data set, and HbVar data as a comprehensive hemoglobinopathy‐specific annotation data set for DASH (Figure [2](#humu23863-fig-0002){ref-type="fig"}). DASH is freely accessible online where three main workflows can be chosen from the homepage, including the hemoglobinopathy inference module, the clinical genotyping module, and the at‐risk assessment module.

![Workflow of DASH. Data resources including LOVD‐China, 22,309 phenotype‐genotype data set, and HbVar data set were mainly used for the clinical genotyping module and at‐risk assessment module. DASH, diagnosis and at‐risk assessment system for hemoglobinopathies; LOVD, Leiden Open Variation Database](HUMU-40-2221-g002){#humu23863-fig-0002}

### 2.2.2. DASH for hemoglobinopathy inference {#humu23863-sec-0090}

The hemoglobinopathy inference module provides a judgment algorithm according to the traditional routine strategy for thalassemia carrier screening (Traeger‐Synodinos et al., [2015](#humu23863-bib-0026){ref-type="ref"}). Hematologic and biochemical tests and subsequent molecular genetic testing are required for identification (Danjou et al., [2015](#humu23863-bib-0006){ref-type="ref"}). Thus, both basic information and hematologic phenotype are required as the input. Basic information includes age, gender, and native places, while hematologic phenotype includes red blood cell indices (HGB, MCH, MCV, and Hb pattern \[Hb A~2~ and Hb F\]). A standard criterion was used for the judgment of the thalassemia trait (Figure S2). For example, a 5‐year‐old girl from Guangdong province of China had the following hematologic phenotype: MCH, 24 pg; MCV, 73 fL; Hb F, 3%; and Hb A~2~, 6% (<http://www.genomed.zju.edu.cn/LOVD3/individuals/00001639>) will be inferred as the β‐thalassemia trait in the output report. In addition, clinical genotyping is highly recommended for this individual; however, individuals with "silent" forms of thalassemia are undetectable because such individuals have normal or borderline red cell indices and/or Hb A~2~ levels (Hallam et al., [2014](#humu23863-bib-0010){ref-type="ref"}). Moreover, it is important to note that iron deficiency alone or co‐exist with the thalassemias can also cause microcytic hypochromic anemia, which could lead to misinterpretation. If an individual is found to be iron‐deficient, it is recommended to repeat the hematologic screen once the individual is iron‐replete (Traeger‐Synodinos et al., [2015](#humu23863-bib-0026){ref-type="ref"}).

### 2.2.3. DASH for clinical genotyping {#humu23863-sec-0100}

The clinical genotyping module consists of two sub‐modules (hemoglobinopathy‐specific annotation and genotype combinatory analysis), which will be executed sequentially. Different format of hemoglobinopathy‐related SNVs and CNVs list can be recognized as inputs, then annotated by the integrated comprehensive hemoglobinopathy‐specific annotation data set. After annotation, disease‐causing and modifier variants will be evaluated for a combined analysis, which ultimately leads to an overall hemoglobinopathy diagnosis, especially for β‐thalassemia. For example, heterozygotes of the β‐variant combined with α‐globin gene triplicates or quadruplicates will be reported as β‐thalassemia intermedia and compound heterozygotes or homozygotes of variants located in or destroying the zinc finger domain of the *KLF1* gene will be reported as atypical thalassemia. For perfect use of this module, the details of the input requirement are on the right side and output interpretation can be obtained in the Q&A from the homepage (<http://www.smuhemoglobinopathy.com/question/#tab=1>).

### 2.2.4. DASH for at‐risk assessment {#humu23863-sec-0110}

At‐risk assessment module has been established for couples, the variant list from individual and spouse are required. Format and examples of variants are provided in the right side of the module. For each individual, clinical genotyping will be performed first to get an overall hemoglobinopathy diagnosis, then combinatory analysis of variants of individual and spouse will report whether or not the offspring of this couple will be at‐risk for hemoglobin disorders. The possible at‐risk genotype and modifier variants of offspring will be reminded to assist the clinicians for comprehensive genetic counseling.

3. DISCUSSION {#humu23863-sec-0120}
=============

The LOVD‐China database, which was first built by Zhejiang University as part of the International Human Variome Project, has properly managed and stored thousands of phenotype‐genotype datasets from China in strict accordance with the regulation of Ministry of Science and Technology of PR China, since 2008 (Burn & Watson, [2016](#humu23863-bib-0004){ref-type="ref"}). The LOVD‐China database has already embodied comprehensive mutation spectra and the phenotypic impact of several diseases, including breast cancer, colorectal cancer, and LQTS (Pan et al., [2011](#humu23863-bib-0018){ref-type="ref"}; Zhang et al., [2010](#humu23863-bib-0031){ref-type="ref"}). In this study, we established the LOVD‐China database for hemoglobinopathies by integrating all the collectible variants corresponding to the candidate genes focusing on a Chinese population, especially 74 functional modifier variants identified from our local 2,087 hemoglobinopathies samples which will make efforts to provide a new target for precise diagnosis of the clinical severity β‐thalassemia. In addition, we developed and validated a DASH aimed to help facilitate the accurate diagnosis and counseling from the results of both traditional approaches and molecular screening of hemoglobinopathies in Chinese. Six globin genes (*HBB*, *HBA1*, *HBA2*, *HBD*, *HBG1*, and *HBG2*) and three nonglobin modifiers (*KLF1*, *BCL11A,* and *HMIP*), which have been shown to possess the greatest efficacy to statistically explain the modest clinical symptoms of β‐thalassemia, were considered as our candidate genes. Notably, other modifier genes of hemoglobinopathies exist which may be relevant to the phenotype of patients. The aim of this study, however, was to portray the most comprehensive mutation spectrum of hemoglobinopathies in a Chinese population and provide a new method for automatic auxiliary diagnosis of hemoglobinopathies.

There is an all‐time difficulty to make an accurate determination of the morbidity for hemoglobinopathies mainly due to complicated environmental factors, medical conditions, and individual difference. Besides, as mentioned before, modifier genes have a significant impact on the severity of hemoglobinopathies. Combination analysis of disease‐causing and modifier variants is considered to be the key factor underlying accurate clinical genotyping (Danjou et al., [2015](#humu23863-bib-0006){ref-type="ref"}). During the era of next‐generation sequencing, the bulk of variants and polymorphisms have been identified in the hemoglobinopathy‐relevant genes, especially in modifier genes, such as the *KLF1*, *BCL11A*, and *HMIP* regions (Basak & Sankaran, [2016](#humu23863-bib-0001){ref-type="ref"}; Orkin, [2016](#humu23863-bib-0017){ref-type="ref"}). More and more variants in these genes were shown to be clinically effective, while the contributions towards clinical severity have shown great ethnic‐specificity. The reawakening of fetal hemoglobin based on these variants holds promise for new therapies for β‐hemoglobinopathies (Bauer, Kamran, & Orkin, [2012](#humu23863-bib-0002){ref-type="ref"}). Our group has accumulated various kinds of samples representing different combinations of disease‐causing variants and modifiers. For example, the *KLF1* gene plays an important role in alleviating the clinical severity of β‐thalassemia (D. Liu et al., [2014](#humu23863-bib-0014){ref-type="ref"}; Tepakhan et al., [2016](#humu23863-bib-0024){ref-type="ref"}). As the cases in Table [3](#humu23863-tbl-0003){ref-type="table"} show, patients with the β^0^/β^0^ genotype, which may result in thalassemia major, turns out to be thalassemia intermediate when they carry functional variants in *KLF1*. Also, alpha multi‐copies are considered to be modifier variants. The heterozygote of β‐thalassemia is asymptomatic, whereas the heterozygote of β‐thalassemia, combined with alpha multi‐copies, results in a thalassemia intermediate phenotype (Mettananda, Gibbons, & Higgs, [2015](#humu23863-bib-0016){ref-type="ref"}; Table [3](#humu23863-tbl-0003){ref-type="table"} and Table S3). Thus, the combined analysis module of DASH is necessary, especially for the accurate clinical genotyping of these samples.

###### 

26 complicated cases of compound heterozygotes in combination with modifier variants

  Major classes                                 Genotypes                                 Number of patients   
  --------------------------------------------- ----------------------------------------- -------------------- ---
  β‐thal modification samples                   4                                         19                   
  α‐Globin gene triplication                    (β^0^/β^0^, ααα/αα)                       3                    0
  (β^0^/β^+^, ααα/αα)                           1                                         0                    
  (β^0^/β^N^ or β^+^/β^N^, ααα/αα or ααα/ααα)   0                                         9                    
  Other modifier variants                       (β^0^ / β^0^) + (*KLF1* ^M^/*KLF1* ^N^)   0                    5
  (β^0^ / β^0^) + 4 significant variants\*      0                                         5                    
  Atypical thalassemia samples                  **0**                                     **3**                
  Microcytic hypochromic anemia                 (*KLF1* ^M^/*KLF1* ^M^)                   0                    3

*Note*: Four significant variants\*: 4 functional variants exerting a significant impact on the clinical severity of β‐thalassemia patients: *HBA1* and *HBA2* disease‐causing variants, rs7482144 (Xmn1), rs61749494 (*BCL11A*), and rs11759553 (*HMIP*). Details of all 26 samples are available in the Supporting Information document (Table S3). The bold values means the number of TM(thalassemia major) or TI(thalassemia intermedia) patients, with no special significance.

Abbreviations: TI, thalassemia intermedia; TM, thalassemia major.

John Wiley & Sons, Ltd.

Molecular screening is an important method for identifying carriers so that we are able to offer counseling and prenatal diagnosis to reduce the birth rate of hemoglobin disorders. There are three groups of variants we considered to be included in the at‐risk assessment for molecular screening. The first group was α‐ or β‐thalassemia variants. The second group was the abnormal hemoglobin variants (Hbs), which may lead to clinical phenotypes, including common variants Hb S (*HBB*:c.20A\>T), Hb E (*HBB*:c.79G\>A), and rare Hb variants, such as Hb Midnapore (*HBB*:c.161C\>T; H. Liu et al., [2016](#humu23863-bib-0015){ref-type="ref"}; Panja, Chowdhury, & Basu, [2016](#humu23863-bib-0019){ref-type="ref"}; Ware, de Montalembert, Tshilolo, & Abboud, [2017](#humu23863-bib-0028){ref-type="ref"}). The benign Hb variants which account for the largest proportion were not included. The third group contained variants resulting in atypical thalassemia (Table [3](#humu23863-tbl-0003){ref-type="table"} and Table S3). For example, compound heterozygotes of variants located in the zinc finger of the *KLF1* gene may lead to microcytic hypochromic anemia (Huang et al., [2015](#humu23863-bib-0012){ref-type="ref"}; Perkins et al., [2016](#humu23863-bib-0020){ref-type="ref"}). At‐risk assessment is highly recommended for the carriers of these variants.

Here, we used hemoglobinopathies as a model to establish the LOVD‐China variant database and DASH system because hemoglobinopathies are the most common monogenic diseases worldwide and are associated with multiple mutations in disease‐causing genes, as well as modifier genes. The LOVD‐China with DASH system is the first automatic auxiliary diagnosis platform for hemoglobinopathies and thus provides a standard platform for screening, diagnosis, and prevention of hemoglobinopathies. Both these websites will be updated and curated with the increasing production in data by molecular screening, traditional diagnostic approaches, and by the submission of clinicians. We hope that LOVD‐DASH will be a paradigm in the online auxiliary diagnosis of genetic disorders and may be an inspiration for other genetic disorders.
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